Equasens H1 margin hits 26.8% as AI and sovereign cloud advance
Equasens, the Euronext-listed provider of digital solutions for European healthcare professionals, has reported first-half 2026 revenue of €124.5m, up 7.3% year-on-year, with current EBITDA rising 11.9% to €33.3m and the EBITDA margin expanding to 26.8% from 25.7% a year earlier. Net profit climbed 10.5% to €20.0m. The results confirm a pattern increasingly visible across European healthtech: software and recurring-subscription models are outpacing hardware cycles, with Equasens' annual recurring revenue (ARR) reaching €111.1m, up 8.8%, providing the kind of revenue visibility that macro investors now price as a strategic premium.
Like-for-like growth was a more modest 1.4%, with the headline improvement driven largely by the Erevo and Novaprove/DIS acquisitions, which contributed €6.3m. That acquisition-led arithmetic is familiar in consolidating verticals, but the more strategically significant number is the 8.4% rise in maintenance and subscription revenue, which reflects the group's deliberate pivot away from one-time hardware and systems sales toward a durable SaaS and cloud base.
Agentic AI and sovereign cloud as structural bets
Chief Executive Denis Supplisson identified three forward-looking growth engines in his commentary: embedding AI into vertical software, developing a sovereign healthcare cloud, and capturing revenue from Wave 2 of France's Ségur digital health reform programme. The Ségur contribution in H1 was still minor at €0.6m, but its deployment schedule runs through the first half of 2027, suggesting a revenue tailwind that has barely begun.
The more structurally interesting signal is the group's explicit ambition to "master the agentic AI layer", autonomous software agents that can automate clinical-administrative tasks, process large patient-data volumes in real time, and surface decision-support for practitioners. This positions Equasens at the intersection of two converging forces: the digitalisation of care pathways mandated by European health-system reform, and the rapid maturation of AI agent frameworks being commercialised across enterprise software broadly. Where general-purpose AI platforms are racing to enter regulated verticals, Equasens is moving from the opposite direction: a deeply embedded workflow incumbent adding intelligence to existing practitioner relationships. LOQUii, its sovereign AI product for real-time caregiver-patient transcription, is the clearest expression of that strategy.
Cross-sector read-across: healthtech, cloud infrastructure and capital allocation
For cross-sector investors, the Equasens results are a useful data point in a broader argument: regulated-vertical SaaS businesses with sticky ARR, sovereign-data-hosting obligations, and government-programme tailwinds are behaving differently from consumer-facing digital health plays. The group's net cash position rose to €93.2m, giving it acquisition optionality in a European healthtech market where smaller software vendors are under pressure from both economic uncertainty and the cost of AI-era product development.
The sovereign cloud angle deserves attention beyond the healthcare sector. European digital sovereignty policy, spanning the EU Data Act, national health data space regulations, and procurement preferences for locally hosted infrastructure, is creating a structural moat for providers that can credibly host sensitive data inside compliant European environments. Equasens' private healthcare cloud, which underpins its SaaS expansion, sits directly in that regulatory tailwind. The same dynamic is playing out in defence, financial services, and public-sector software across the continent, as hyperscaler dependency becomes a geopolitical risk rather than merely a procurement preference. Capital allocators building exposure to European digital sovereignty themes may find the healthtech vertical underrepresented in their portfolios relative to the policy signals now accumulating.
The group's Medical Solutions division recorded a small operating loss of €0.2m as it transforms legacy offerings and invests in new product lines, a temporary drag that management frames as transition cost rather than structural weakness. With Q3 revenue due on 29 October 2026, the pace of Ségur Wave 2 uptake and early agentic-AI commercialisation will be the metrics worth watching.